Summary of Sensei Biotherapeutics and Faeth Therapeutics Acquisition Conference Call Company and Industry Overview - **Company**: Sensei Biotherapeutics (NasdaqGM:SNSE) - **Acquisition Target**: Faeth Therapeutics - **Industry**: Biotechnology, specifically focused on cancer treatment Key Points and Arguments 1. **Acquisition Announcement**: Sensei Biotherapeutics announced the acquisition of Faeth Therapeutics, which includes a concurrent financing and changes to the leadership team and board of directors [2][6] 2. **Strategic Rationale**: The acquisition is seen as a means to maximize shareholder value and is expected to create significant value for stockholders [6] 3. **Faeth's Pipeline**: Faeth is a clinical-stage company developing multi-node therapies aimed at blocking cancer growth signals, with its lead asset, PIKTOR, showing promising safety and efficacy data [6][7] 4. **Financing Details**: Sensei entered into a $200 million private placement with support from leading healthcare investors, which will strengthen its financial position [8] 5. **Cash Runway**: The combined cash from the private placement and existing funds is expected to extend Sensei's cash runway through multiple clinical milestones [8] 6. **Leadership Changes**: Anand Parikh, former CEO and co-founder of Faeth, has joined Sensei as COO and a board member [9] 7. **PIKTOR Overview**: PIKTOR is an investigational oral combination therapy targeting the PI3K/AKT/mTOR pathway, designed to improve tolerability and efficacy compared to traditional treatments [10] 8. **Clinical Trial Results**: In a phase 1b trial, PIKTOR achieved a 47% overall response rate in heavily pre-treated patients with various cancers, including an 80% response rate in endometrial cancer patients [11] 9. **Future Trials**: PIKTOR is currently in phase 2 trials for endometrial cancer, with plans for additional studies in breast cancer and other tumor types [12] 10. **Market Potential**: The focus on cancers with mutations in the PI3K/AKT/mTOR pathway presents a significant market opportunity, particularly as treatment standards evolve towards combination strategies [13] 11. **Preclinical Pipeline**: In addition to PIKTOR, Sensei has a preclinical pipeline that includes therapies for rectal cancer and pediatric rare diseases [13] 12. **Acquisition Structure**: The acquisition was structured as a stock-for-stock merger, with Faeth's equity exchanged for Sensei common stock and newly created Series B non-voting convertible preferred stock [15] 13. **Ownership Post-Acquisition**: Post-acquisition, Faeth's equity holders will own approximately 40.8% of Sensei's common stock, while private placement investors will own about 54.3% [17] 14. **Use of Proceeds**: Proceeds from the private placement will primarily be used to advance PIKTOR for key clinical readouts [17] Additional Important Information - **Forward-Looking Statements**: The call included forward-looking statements regarding the expected effects and opportunities related to the acquisition, which involve risks and uncertainties [3][4] - **Investor Communication**: Investors are encouraged to read the proxy statement and other relevant materials filed with the SEC for important information regarding the transactions [5] - **Future Updates**: Sensei plans to provide updates on the progress of its clinical trials and the integration of Faeth in the coming weeks and months [19]

Fiverr (NYSE:FVRR) Q4 2025 Earnings call February 18, 2026 08:30 AM ET Company ParticipantsMali Greenstein - VP of Investor RelationsMicha Kaufman - Founder and CEOOfer Katz - President and CFOConference Call ParticipantsBernie McTernan - AnalystEric Sheridan - Equity Research AnalystMarvin Fong - Equity Research AnalystMatthew Condon - AnalystNat Schindler - Senior AnalystRohit Kulkarni - Equity Research AnalystRonald Josey - Equity Research AnalystNone - AnalystNone - AnalystNone - AnalystOperator``Please ...

Cinemark (NYSE:CNK) Q4 2025 Earnings call February 18, 2026 08:30 AM ET Company ParticipantsChanda Brashears - SVP of Investor RelationsDrew Crum - Managing DirectorEric Wold - Executive Director of Equity ResearchMelissa Thomas - CFOMike Hickey - Managing Director and Tax DirectorOmar Mejias - VP of Equity ResearchSean Gamble - President and CEOStephen Laszczyk - VPConference Call ParticipantsChad Beynon - Managing Director and Senior AnalystDavid Karnovsky - Senior Research AnalystEric Handler - Managing ...

Travel + Leisure (NYSE:TNL) Q4 2025 Earnings call February 18, 2026 08:30 AM ET Company ParticipantsAndrew Burns - VP of Investor RelationsErik Hoag - CFOMichael Brown - President and CEOStephen Grambling - Managing Director and Head of U.S. Gaming, Lodging and Leisure ResearchConference Call ParticipantsBen Chaiken - Managing Director and Senior Equity AnalystBrandt Montour - Director and Equity Research AnalystChris Woronka - Director and Senior Equity AnalystDavid Katz - Managing Director and Equity Rese ...

Similarweb (NYSE:SMWB) Q4 2025 Earnings call February 18, 2026 08:30 AM ET Company ParticipantsAdam Hotchkiss - Vice President of Emerging Software Equity ResearchArjun Bhatia - Co-Group Head of Technology, Media, and CommunicationsMaoz Lakovski - Chief Business OfficerOr Offer - CEO and Co-FounderPatrick Walravens - Managing Director and Director of Technology ResearchRaimo Lenschow - Managing DirectorRami Myerson - VP of Investor RelationsRan Vered - CFOConference Call ParticipantsKen Wong - Managing Dire ...

La-Z-Boy (NYSE:LZB) Q3 2026 Earnings call February 18, 2026 08:30 AM ET Company ParticipantsBobby Griffin - Managing Director of Equity ResearchMark Becks - Director of Investor Relations and Corporate DevelopmentMelinda Whittington - Board Chair, President, and CEOTaylor Luebke - SVP and CFOConference Call ParticipantsAnthony Lebiedzinski - Senior Equity Research AnalystTaylor Zick - Analyst in the Research DivisionOperatorPlease note this conference is being recorded. I will now turn the conference over t ...

ICL Group (NYSE:ICL) Q4 2025 Earnings call February 18, 2026 08:30 AM ET Company ParticipantsAnantha Desikan - COOAviram Lahav - CFOElad Aharonson - CEOJoel Jackson - Managing Director of Equity ResearchPeggy Reilly Tharp - VP of Global Investor RelationsRaviv Zoller - ChairmanConference Call ParticipantsBenjamin Theurer - Equity Research AnalystDaanish Rizwan - SVP and Equity Research AnalystOperatorGood morning, ladies and gentlemen, and welcome to the ICL fourth quarter 2025 earnings international confer ...

Enpro (NYSE:NPO) Q4 2025 Earnings call February 18, 2026 08:30 AM ET Company ParticipantsEric Vaillancourt - President and CEOIsaac Sellhausen - Associate in Equity ResearchJames Gentile - VP of Investor RelationsJoe Bruderek - EVP and CFOConference Call ParticipantsJeff Hammond - Managing Director and Equity Research AnalystSteve Ferazani - Equity Research AnalystOperatorIt's now my pleasure to turn the call over to your host, James Gentile, Vice President of Investor Relations for Enpro. Please go ahead, ...

TFI International (NYSE:TFII) Q4 2025 Earnings call February 18, 2026 08:30 AM ET Company ParticipantsAlain Bédard - Chairman, President and CEODavid Saperstein - CFOKen Hoexter - Managing DirectorConference Call ParticipantsBrian Ossenbeck - Equity Research AnalystBruce Chan - Equity Research AnalystCameron Doerksen - Equity Research AnalystJason Seidl - Equity Research AnalystJordan Alliger - Equity Research AnalystKonark Gupta - Equity Research AnalystThomas Wadewitz - Senior Equity Research AnalystWalte ...

Similarweb (NYSE:SMWB) Q4 2025 Earnings call February 18, 2026 08:30 AM ET Company ParticipantsAdam Hotchkiss - Vice President of Emerging Software Equity ResearchArjun Bhatia - Co-Group Head of Technology, Media, and CommunicationsKincaid LaCorte - Equity Research AssociateMaoz Lakovski - Chief Business OfficerOr Offer - CEO and Co-FounderRaimo Lenschow - Managing DirectorRami Myerson - VP of Investor RelationsRan Vered - CFOConference Call ParticipantsKen Wong - Managing Director and Senior AnalystLuke Ho ...